PenderFund Capital Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

PenderFund Capital Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-700	Closed	-$16K	–	176
2021 Q3	$16K	Buy	+700	New	+$8.18K	﹤0.01%	111

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

PenderFund Capital Management's TRIL Position: Q4 2021 in Review

PenderFund Capital Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 700 shares — an estimated $16K sold.

PenderFund Capital Management first reported a position in TRIL in Q3 2021 and held it in 1 quarter. The position peaked at $16K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

PenderFund Capital Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
PenderFund Capital Management sold 700 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $16K.
PenderFund Capital Management first reported a position in Trillium Therapeutics Inc. in Q3 2021 and held it in 1 quarter.
PenderFund Capital Management's Trillium Therapeutics Inc. position peaked at $16K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on PenderFund Capital Management's 13F filing for Q4 2021, filed 16 Feb 2022.